^
    1year
    MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer. (PubMed, Cell Biosci)
    "miR-181a is a key factor controlling the STING pathway and driving PARPi and platinum-based drug resistance in TNBC and OvCa. The miR-181a-STING axis can be used as a potential marker for predicting PARPi responses in TNBC and OvCa tumors."
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • IFNG (Interferon, gamma) • BRCA (Breast cancer early onset) • STING (stimulator of interferon response cGAMP interactor 1) • MIR181A1 (MicroRNA 181a-1)
    |
    BRCA1 mutation • HER-2 negative • IFNG-L • BRCA mutation
    |
    HTG EdgeSeq miRNA Whole Transcriptome Assay
    |
    Lynparza (olaparib)
    1year
    Diagnostic miRNA Signatures in Paired Tumor, Plasma, and Urine Specimens From Renal Cell Carcinoma Patients. (PubMed, Clin Chem)
    "This integrative study found diagnostic miRs/cfmiRs for RCC patients, which were validated using The Cancer Genome Atlas data sets. Distinctive cfmiR signatures found in urine may have clinical utility for the diagnosis of RCC."
    Journal
    |
    MIR155 (MicroRNA 155) • MIR21 (MicroRNA 21) • MIR210 (MicroRNA 210) • MIR885 (MicroRNA 885) • MIR106B (MicroRNA 106b) • MIR122 (MicroRNA 122) • MIR127 (MicroRNA 127)
    |
    HTG EdgeSeq miRNA Whole Transcriptome Assay
    2years
    Bone Marrow Fibrosis Is Associated with Non-Response to CD19 CAR-T Therapy (ASH 2022)
    DE and pathway enrichment analysis of NR and SR pre-CAR infusion samples showed significant NR up-regulation of genes in Skeletal System (p < 0.001) and Connective Tissue Development (p < 0.001), Epithelial to Mesenchymal Transition (p < 0.001), and ECM Structural Constituent (p < 0.001) pathways. Cytokine signaling was not significantly different between groups. Several fibrosis-associated genes, TGFB3 (5.67x, p = 0.009), PRELP (19.26x, p = 0.001), EGR1 (4.85x, p = 0.005), and DUSP1 (4.51x, p = 0.009), were among the ten most significantly upregulated genes.
    IO biomarker
    |
    CD19 (CD19 Molecule) • PAX5 (Paired Box 5) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1) • DUSP1 (Dual Specificity Phosphatase 1) • EGR1 (Early Growth Response 1)
    |
    HTG EdgeSeq miRNA Whole Transcriptome Assay
    over2years
    Urine Cell-Free MicroRNAs in Localized Prostate Cancer Patients. (PubMed, Cancers (Basel))
    These urine cfmiRs may have potential utility in diagnosing early-stage PCa and complementing or improving currently available PCa screening assays. Future studies may validate the findings.
    Journal
    |
    HTG EdgeSeq miRNA Whole Transcriptome Assay
    over2years
    HTG expands features of proprietary HTG EdgeSeq Technology (HTG Molecular Diagnostics Press Release)
    "HTG Molecular Diagnostics, Inc...announced that it has improved the sample preparation protocol for its miRNA Whole Transcriptome Assay (miRNA WTA) so that it is now harmonized with the HTG Transcriptome Panel (HTP)...The harmonized protocol is designed to enable customers to process a single sample with HTG’s nearly 20,000 gene mRNA and 2,000+ miRNA transcriptome panels using a single sample lysate."
    Clinical
    |
    HTG EdgeSeq miRNA Whole Transcriptome Assay • HTG Transcriptome Panel
    over3years
    [VIRTUAL] Diagnostic ability of four cell-free miRNA signatures pre- and post-nephrectomy concordantly found in the tumor and blood from patients with renal cell carcinoma. (ASCO 2021)
    Our results propose a four cfmiR signature as a potential diagnostic/monitoring urine biomarker that is also detectable in the plasma and tumor tissues from RRC . Further studies to validate these cfmiRNAs as biomarkers for RCC in blood and urine are ongoing.
    Clinical
    |
    MIR23b (MicroRNA 23b) • MIR30D (MicroRNA 30d)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel • HTG EdgeSeq miRNA Whole Transcriptome Assay
    almost4years
    Circulating MicroRNAs in Relation to Esophageal Adenocarcinoma Diagnosis and Survival. (PubMed, Dig Dis Sci)
    "While they require replication, these findings suggest that circulating miRNAs may be associated with EA diagnosis and survival."
    Journal
    |
    MIR425 (MicroRNA 425)
    |
    HTG EdgeSeq miRNA Whole Transcriptome Assay